Author:
Gaur Aditya H,Cotton Mark F,Rodriguez Carina A,McGrath Eric J,Helström Elizabeth,Liberty Afaaf,Natukunda Eva,Kosalaraksa Pope,Chokephaibulkit Kulkanya,Maxwell Heather,Wong Pamela,Porter Danielle,Majeed Sophia,Yue Mun Sang,Graham Hiba,Martin Hal,Brainard Diana M,Pikora Cheryl
Subject
Developmental and Educational Psychology,Pediatrics, Perinatology and Child Health
Reference28 articles.
1. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults;Gallant;J Acquir Immune Defic Syndr,2017
2. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile;Tsiang;Antimicrob Agents Chemother,2016
3. Zhang H, Custodio JM, Wei X, et al. Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. Conference on Retroviruses and Opportunistic Infections; Seattle, WA; Feb 13–16, 2017 (abstr 40).
4. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results;Arribas;J Acquir Immune Defic Syndr,2017
5. Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials;Gupta;AIDS,2019
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献